{"id":"moracizine","brandName":"moracizine","genericName":"moracizine","companyId":"unknown","companyName":"","phase":"unknown","status":"active","modality":"","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"","enrichmentLevel":3,"visitCount":0,"mechanism":{"target":"Sodium channel protein type 5 subunit alpha"},"administration":{},"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":["NCT00000526","NCT00000556","NCT00000504"],"indications":{"approved":[{"name":"Ventricular arrhythmia","diseaseId":"ventricular-arrhythmia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[{"nctId":"NCT00000526","phase":"Phase 3","title":"","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","isPivotal":true,"enrollment":0,"indication":"Cardiovascular Diseases, Coronary Disease","completionDate":"1998-03"},{"nctId":"NCT00000556","phase":"Phase 3","title":"","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","isPivotal":true,"enrollment":0,"indication":"Arrhythmia, Atrial Fibrillation","completionDate":"2002-09"},{"nctId":"NCT00000504","phase":"Phase 2","title":"","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","isPivotal":false,"enrollment":0,"indication":"Arrhythmia, Cardiovascular Diseases","completionDate":"1985-09"}],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}